Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Blood

Volumn 129, Issue 10, 2017, Pages 1380-1388

  Merryman, Reid W ^a   Kim, Haesook T ^b   Zinzani, Pier Luigi ^c   Carlo Stella, Carmelo ^d,e   Ansell, Stephen M ^f   Perales, Miguel Angel ^g   Avigdor, Abraham ^h   Halwani, Ahmad S ⁱ   Houot, Roch ^j,k   Marchand, Tony ^j   Dhedin, Nathalie ^l   Lescaut, Willy ^m   Thiebaut Bertrand, Anne ⁿ   François, Sylvie ^o   Stamatoullas Bastard, Aspasia ^p   Rohrlich, Pierre Simon ^q   Wallet, Hélène Labussière ^r   Castagna, Luca ^d,e   Santoro, Armando ^d,e   Bachanova, Veronika ^s   Bresler, Scott C ^a   Srivastava, Amitabh ^a   Kim, Harim ^t   Pesek, Emily ^a   Chammas, Marie ^a   Reynolds, Carol ^a   Ho, Vincent T ^a   Antin, Joseph H ^a   Ritz, Jerome ^a   Soiffer, Robert J ^a   Armand, Philippe ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f MAYO CLINIC   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h SHEBA MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY OF UTAH   (United States)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k INSERM   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m Centre Hospitalier Princesse Grace   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o ANGERS UNIVERSITY HOSPITAL   (France)

^p CENTRE HENRI BECQUEREL   (France)

^q UNIVERSITY HOSPITAL OF NICE   (France)

^r HOSPICES CIVILS DE LYON   (France)

^s UNIVERSITY OF MINNESOTA   (United States)

^t Seoul National University   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; BUSULFAN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEFIBROTIDE; FLUDARABINE; IPILIMUMAB; L SELECTIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RAPAMYCIN; STEROID; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE KIDNEY FAILURE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER SURVIVAL; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; ENGRAFTMENT SYNDROME; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNE RESPONSE; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; LYMPHOCYTE SUBPOPULATION; MALE; MORTALITY RATE; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT FEVER; REGULATORY T LYMPHOCYTE; RELAPSE; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; THERAPY EFFECT; TIME TO TREATMENT; TOXIC HEPATITIS; TRANSPLANTATION CONDITIONING; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY RADIATION; ALLOGRAFT; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; LYMPHOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PROCEDURES; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ALLOGRAFTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 85015624944     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-738385     Document Type: Article

References (38)

1. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8): 1537-1544.
2. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800.
3. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4): 311-319.
4. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online ahead of print 27 June 2016]. J Clin Oncol. 2016;JCO673467.
5. Highlights of Prescribing Information-Nivolumab. US Food Drug Adm. 2014;1-20.
6. Ding W, Dong H, Call TG, et al. PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including richter transformation: an early efficacy report from a phase 2 trial (MC1485) [abstract]. Blood. 2015;126(23). Abstract 834.
7. Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23): 2698-2704.
8. Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102(18): 1388-1397.
9. Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P. The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation. Immunity. 2016;44(1):143-154.
10. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(17):3062-3073.
11. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272-1277.
12. Herbaux C, Gauthier J, Brice P, et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC [abstract]. Blood. 2015; 126(23). Abstract 3979.
13. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375(2):143-153.
14. Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5): 646-657.
15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
16. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(9):893-898.
17. Maiolino A, Biasoli I, Lima J, Portugal AC, Pulcheri W, Nucci M. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant. 2003;31(5):393-397.
18. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(3):455-462.
19. Robinson SP, Sureda A, Canals C, et al; Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230-238.
20. Carreras E, Diaz-Beyá M, Rosinol L, Martinez C, Fernández-Avilés F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011; 17(11):1713-1720.
21. Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10): 1851-1860.
22. Armand P, Kim HT, Sainvil M-M, et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173(1):96-104.
23. Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7): 938-947.
24. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008;14(4):418-425.
25. Ghosh N, Karmali R, Rocha V, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34(26):3141-3149.
26. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-3671.
27. Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study-a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2): 310-317.
28. Anderlini P, Saliba RM, Ledesma C, et al. Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22(7):1333-1337.
29. Pang N, Duan X, Jiang M, et al. Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro. Int J Clin Exp Pathol. 2015;8(8): 8892-8901.
30. Fujioka T, Tamaki H, Ikegame K, et al. Frequency of CD4(1)FOXP3(1) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. Bone Marrow Transplant. 2013; 48(6):859-864.
31. Amarnath S, Mangus CW, Wang JCM, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011;3(111): 111ra120.
32. Asano T, Kishi Y, Meguri Y, et al. PD-1 signaling has a critical role in maintaining regulatory T cell homeostasis; implication for Treg depletion therapy by PD-1 blockade [abstract]. Blood. 2015;126(23). Abstract 848.
33. Keir ME, Latchman YE, Freeman GJ, Sharpe AH. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol. 2005; 175(11):7372-7379.
34. Thangavelu G, Parkman JC, Ewen CL, Uwiera RR, Baldwin TA, Anderson CC. Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis. J Autoimmun. 2011; 36(3-4):301-312.
35. Blank C, Brown I, Marks R, Nishimura H, Honjo T, Gajewski TF. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol. 2003;171(9):4574-4581.
36. Daley SR, Hu DY, Goodnow CC. Helios marks strongly autoreactive CD41 T cells in two major waves of thymic deletion distinguished by induction of PD-1 or NF-kB. J Exp Med. 2013;210(2):269-285.
37. Highlights of Prescribing Information-Pembrolizumab. US Food Drug Adm. 2014;1-16.
38. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007;13(12):1461-1468.